SCHEMBL5536962

SCHEMBL5536962

CC(=O)N(C)c1ccccc1[O]

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSPO P30536 1/20 0.53
FSCN1 Q16658 1/20 0.44
SMN1; SMN2 Q16637 5/20 0.42
ALDH1A1 P00352 4/20 0.42
GAA P10253 3/20 0.42
MAPT P10636 2/20 0.42
TSHR P16473 2/20 0.42
TP53 P04637 1/20 0.42
ALOX15 P16050 1/20 0.37
HSD17B10 Q99714 1/20 0.37
ELANE P08246 1/20 0.37
LMNA P02545 1/20 0.36
OPRM1 P35372 1/20 0.35
OPRL1 P41146 1/20 0.35
KMT2A Q03164 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
KDM4E B2RXH2 1/20 0.35
SIGMAR1 Q99720 1/20 0.34
CA12 O43570 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17707224 0.80 GAA (0.59) TSPOSMN1; SMN2ALDH1A1GAAMAPT
SCHEMBL15224071 0.80 TSPO (0.55) TSPOFSCN1SMN1; SMN2ALDH1A1GAA
SCHEMBL5536970 0.80 TSPO (0.55) TSPOFSCN1SMN1; SMN2ALDH1A1GAA
SCHEMBL945008 0.79 TSPO (0.50) TSPOFSCN1SMN1; SMN2ALDH1A1GAA
SCHEMBL5042970 0.78 TSPO (0.53) TSPOFSCN1SMN1; SMN2ALDH1A1LMNA
SCHEMBL29674730 0.78 TSPO (0.53) TSPOFSCN1SMN1; SMN2ALDH1A1LMNA
SCHEMBL12522957 0.78 TSPO (0.49) TSPOFSCN1SMN1; SMN2ALDH1A1GAA
SCHEMBL2624369 0.78 TSPO (0.49) TSPOFSCN1SMN1; SMN2ALDH1A1GAA
SCHEMBL8342773 0.77 TSPO (0.51) TSPOFSCN1SMN1; SMN2ALDH1A1GAA
SCHEMBL10626622 0.77 TSPO (0.51) TSPOFSCN1SMN1; SMN2ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 TSPO 1596/4885FSCN1 3716/4885SMN1; SMN2 3985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.